Rita Rubin's JAMA publication on FDA (VRBPAC) nightmarish seeking of vaccine for XBB.1.5 sub-variant (monovalent) tells us how reckless, inept FDA is! XBB.1.5 will be gone! (EG 5, XBB.2.3, XBB 1.16)

by Paul Alexander

Original antigenic sin (immune priming), ADEI/ADED; the concern is that mismatch between dominant sub-variant & vaccine-induced antibodies will drive selective pressure for more infectious subvariants




Current bivalent COVID-19 vaccines take aim at the ancestral SARS-CoV-2 strain, first identified in December 2019 and targeted by the original monovalent vaccines, and the BA.4 and BA.5 Omicron subvariants, whose spike proteins are identical.

Even before the bivalent vaccines became available last September, though, the ancestral SARS-CoV-2 strain had disappeared, edged out by a Greek alphabet of variants leading up to Omicron and its offspring.’

More updated forecasting shows us that XBB.1.5 will no longer be the dominant variant by the time the new monovalent XBB.1.15 vaccine comes on tap (see my substack above)…

McCullough’s recent published forecast below is dated by one period (showing XBB.1.5) dominating at 27% but my above forecast shows EG5, XBB.1.16, XBB 2.3 as surging as XBB.1.5 fades (projected)):

See my prior substack:

Excellent stack by McCullough worth the read:

Courageous Discourse™ with Dr. Peter McCullough & John Leake
FDA VRBPAC Hopelessly Chasing Outgoing XBB.1.5 as Fall Target
By Peter A. McCullough, MD, MPH From Rita Rubin, Science Reporter for JAMA: “On June 15, members of the US Food and Drug Administration’s (FDA) Vaccine and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend updating the COVID-19 vaccine composition to a monovalent XBB lineage…
Read more